METHODS OF TREATING DISEASE WITH DICHLORPHENAMIDE
Provided herein is a method for treating primary hyperkalemic periodic paralysis, primary hypokalemic periodic paralysis, and related variants. The method comprises administering to the subject a therapeutically effective amount of dichlorphenamide, or a pharmaceutically acceptable salt thereof, informing the subject to notify a medical professional if the subject experiences symptoms of cognitive impairment, and adjusting the therapeutically effective amount of dichlorphenamide, or a pharmaceutically acceptable salt thereof, when the subject is experiencing symptoms of cognitive impairment. The subject or a medical care worker may be informed that administration of the dichlorphenamide, or a pharmaceutically acceptable salt thereof, may result in increased risk of the subject experiencing symptoms of cognitive impairment.
1 . A method for treating primary hyperkalemic periodic paralysis, primary hypokalemic periodic paralysis, and related variants in a subject in need thereof, the method comprising:
administering to the subject an initial dose of dichlorphenamide, or a pharmaceutically acceptable salt thereof wherein the initial dose is 50 mg once daily, and
informing the subject to notify a medical professional if the subject experiences symptoms of memory lapse.
2 . The method of claim 1 , further comprising informing the subject or a medical care worker that administration of the dichlorphenamide, or a pharmaceutically acceptable salt thereof, may result in symptoms of memory lapse.
3 . (canceled)
4 . (canceled)
5 . (canceled)
6 . (canceled)
7 . (canceled)
8 . (canceled)
9 . (canceled)
10 . (canceled)
11 . (canceled)
12 . (canceled)
13 . (canceled)
14 . (canceled)
15 . (canceled)
16 . A method for treating primary hyperkalemic periodic paralysis, primary hypokalemic periodic paralysis, and related variants in a subject in need thereof, the method comprising:
administering to the subject an initial dose of dichlorphenamide, or a pharmaceutically acceptable salt thereof, wherein the initial dose is 50 mg twice daily,
informing the subject to notify a medical professional if the subject experiences symptoms of memory lapse, and
if the subject experiences memory lapse, reducing the dose of dichlorphenamide, or a pharmaceutically acceptable salt there, to 50 mg once daily.
17 . The method of claim 1 , wherein if the subject does not experience memory lapse, the dose of dichlorphenamide, or a pharmaceutically acceptable salt thereof, is increased to 50 mg twice daily.